<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Braz J Cardiovasc Surg</journal-id><journal-id journal-id-type="iso-abbrev">Braz J Cardiovasc Surg</journal-id><journal-id journal-id-type="publisher-id">rbccv</journal-id><journal-title-group><journal-title>Brazilian Journal of Cardiovascular Surgery</journal-title></journal-title-group><issn pub-type="ppub">0102-7638</issn><issn pub-type="epub">1678-9741</issn><publisher><publisher-name>Sociedade Brasileira de Cirurgia Cardiovascular</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29617506</article-id><article-id pub-id-type="pmc">5873775</article-id><article-id pub-id-type="doi">10.21470/1678-9741-2017-0134</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Chronic Chagas Cardiomyopathy Patients and Resynchronization Therapy:
a Survival Analysis</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Menezes Junior</surname><given-names>Ant&#x000f4;nio da Silva</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="c1"/><role>MD, PhD</role></contrib><contrib contrib-type="author"><name><surname>Lopes</surname><given-names>Cynthia Caetano</given-names></name><xref ref-type="aff" rid="aff1">1</xref><role>MD</role></contrib><contrib contrib-type="author"><name><surname>Cavalcante</surname><given-names>Patr&#x000ed;cia Freire</given-names></name><xref ref-type="aff" rid="aff1">1</xref><role>MD</role></contrib><contrib contrib-type="author"><name><surname>Martins</surname><given-names>Ed&#x000e9;sio</given-names></name><xref ref-type="aff" rid="aff1">1</xref><role>MD</role></contrib><aff id="aff1">
<label>1</label> Escola de Ci&#x000ea;ncias M&#x000e9;dicas, Farmac&#x000ea;uticas
e Biom&#x000e9;dicas of the Pontif&#x000ed;cia Universidade Cat&#x000f3;lica de
Goi&#x000e1;s (PUC-GO), Goi&#x000e2;nia, GO, Brazil. </aff></contrib-group><author-notes><corresp id="c1">Correspondence Address: Ant&#x000f4;nio da Silva Menezes Junior,
Pontif&#x000ed;cia Universidade Cat&#x000f3;lica de Goi&#x000e1;s, Rua 95,
n&#x000ba; 99, Setor Sul - Goi&#x000e2;nia, GO, Brazil - Zip code: 74083-100.
E-mail: <email>a.menezes.junior@uol.com.br</email></corresp></author-notes><pub-date pub-type="epub-ppub"><season>Jan-Feb</season><year>2018</year></pub-date><!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' --><pub-date pub-type="ppub"><season>Jan-Feb</season><year>2018</year></pub-date><volume>33</volume><issue>1</issue><fpage>82</fpage><lpage>88</lpage><history><date date-type="received"><day>01</day><month>4</month><year>2017</year></date><date date-type="accepted"><day>09</day><month>7</month><year>2017</year></date></history><permissions><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an Open Access article distributed under the terms of the
Creative Commons Attribution License, which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is
properly cited.</license-p></license></permissions><abstract><sec><title>Introduction</title><p>Chagas disease represents an important health problem with socioeconomic
impacts in many Latin-American countries. It is estimated that 20% to 30% of
the people infected by <italic>Trypanosoma cruzi</italic> will develop
chronic Chagas cardiomyopathy (CCC), which is generally accompanied by heart
failure (HF). Cardiac resynchronization therapy (CRT) may be indicated for
patients with HF and electromechanical dysfunctions.</p></sec><sec><title>Objective</title><p>The primary endpoint of this study was to analyze the response to CRT in
patients with CCC, while the secondary endpoint was to estimate the survival
rates of CRT responder patients.</p></sec><sec><title>Methods</title><p>This is an observational, cross-sectional and retrospective study. The
records of 50 patients with CRT pacing devices implanted between June 2009
and March 2017 were analyzed. For statistical analyses, Pearson's
correlation was used along with Student's t-test, and survival was analyzed
using the Kaplan-Meier method. A <italic>P</italic> value of &#x0003c;0.05 was
considered significant.</p></sec><sec><title>Results</title><p>Out of 50 patients, 56% were male, with a mean age of 63.4&#x000b1;13.3 years
and an average CRT duration of 61.2&#x000b1;21.7 months. The mean QRS
duration was 150.12&#x000b1;12.4 ms before and 116.04&#x000b1;2.2 ms after the
therapy (<italic>P</italic>&#x0003c;0.001). The mean left ventricular ejection
fractions (LVEF) were 29&#x000b1;7% and 39.1&#x000b1;12.2% before and after
CRT, respectively (<italic>P</italic>&#x0003c;0.001). A total of 35 (70%)
patients had a reduction of at least one New York Heart Association (NYHA)
functional class after six months of therapy (<italic>P</italic>=0.014). The
survival rate after 72 months was 45%.</p></sec><sec><title>Conclusion</title><p>This study showed clinical improvement and a nonsignificant survival rate in
patients with CCC after the use of CRT.</p></sec></abstract><kwd-group><kwd>Chagas Disease</kwd><kwd>Cardiac Resynchronization Therapy</kwd><kwd>Heart Failure</kwd></kwd-group></article-meta></front><body><table-wrap id="t4" orientation="portrait" position="anchor"><table frame="hsides" rules="groups"><colgroup span="1"><col width="5%" span="1"/><col width="43%" span="1"/><col width="3%" span="1"/><col width="5%" span="1"/><col width="43%" span="1"/></colgroup><thead><tr><th align="left" colspan="2" style="background-color:#e6e7e8" rowspan="1">Abbreviations,
acronyms &#x00026; symbols</th><th align="center" rowspan="1" colspan="1">&#x000a0;</th><th align="center" colspan="2" style="background-color:#e6e7e8" rowspan="1">&#x000a0;</th></tr></thead><tbody><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">ACE</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Angiotensin-converting
enzyme</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">LVESV</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Left ventricular end
systolic volume</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">ARB</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Angiotensin-receptor
blockers</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">MADIT</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Multicenter Automatic
Defibrillator ImplantationTrial</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">CARE-HF</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Cardiac
Resynchronization-Heart Failure Trial</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">MIRACLE</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Multicenter InSync
Randomized Clinical Evaluation</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">CCC</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Chronic Chagas
cardiomyopathy</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">NHC</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= National Health
Council</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">CI</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Confidence interval</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">NYHA</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= New York Heart
Association</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">COMPANION</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Comparison of Medical
Therapy, Pacing and Defibrillation in Heart Failure</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">PSVT</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Paroxysmal
supraventricular tachycardia</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">CRT</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Cardiac
resynchronization therapy</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">RAFT</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">=
Resynchronization/Defibrillation for Ambulator Heart Failure Trial</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">HF</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Heart failure</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">RBBB</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Right bundle branch
block</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">HR</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Hazard ratio</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">REVERSE</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= The Resynchronization
Reverse Remodeling in Systolic Left Ventricular Dysfunction</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">ICD</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Implantable cardioverter
defibrillator</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">VT</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Ventricular
tachycardia</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">LAFB</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Left anterior fascicular
block</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">WHO</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= World Health
Organization</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">LBBB</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Left bundle branch
block</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">LVEF</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Left ventricular
ejection fraction</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">&#x000a0;</td></tr></tbody></table></table-wrap><sec sec-type="intro"><title>INTRODUCTION</title><p>According to the World Health Organization (WHO), Chagas disease is an important
health problem with socioeconomic impacts in many Latin-American
countries<sup>[<xref rid="r1" ref-type="bibr">1</xref>]</sup>p&#x0003e;. Chagas disease, also known as American
Trypanosomiasis, is caused by the protozoan <italic>Trypanosoma cruzi</italic>, and
WHO estimates that there are approximately 8 million people infected
worldwide<sup>[<xref rid="r1" ref-type="bibr">1</xref>]</sup>p&#x0003e;.</p><p>It is known that only 20% to 30% of those infected with <italic>Trypanosoma
cruzi</italic> will develop chronic Chagas cardiomyopathy (CCC), one of its most
frequent and severe clinical forms<sup>[<xref rid="r2" ref-type="bibr">2</xref>,<xref rid="r3" ref-type="bibr">3</xref>]</sup>p&#x0003e;. This
disease causes loss of myocardial contractile function, dilation of cardiac
chambers, and destruction of cardiomyocytes as well as fibrosis and scars. These
patients may develop arrhythmias, apical aneurysms, thromboembolisms, sudden death,
and heart failure (HF)<sup>[<xref rid="r3" ref-type="bibr">3</xref>]</sup>p&#x0003e;. The progression of HF often leads to changes in
intracardiac electrical conduction, progressing with atrioventricular,
intraventricular or interventricular conduction disorders<sup>[<xref rid="r4" ref-type="bibr">4</xref>]</sup>p&#x0003e;.</p><p>The pharmacotherapy agents used in the treatment of HF are well established and
widely used<sup>[<xref rid="r5" ref-type="bibr">5</xref>]</sup>p&#x0003e;.
Recently, in addition to pharmacotherapy, cardiac pacing has also been a treatment
option with major impact on quality of life and reduction of
mortality<sup>[<xref rid="r6" ref-type="bibr">6</xref>]</sup>p&#x0003e;.</p><p>In the last decade, several multicenter studies - such as COMPANION (Comparison of
Medical Therapy, Pacing and Defibrillation in Heart Failure)<sup>[<xref rid="r7" ref-type="bibr">7</xref>]</sup>p&#x0003e;, CARE-HF (Cardiac
Resynchronization-Heart Failure Trial)<sup>[<xref rid="r8" ref-type="bibr">8</xref>]</sup>p&#x0003e;, REVERSE (The Resynchronization Reverse
Remodeling in Systolic Left Ventricular Dysfunction)<sup>[<xref rid="r9" ref-type="bibr">9</xref>]</sup>p&#x0003e;, MIRACLE (Multicenter
InSync Randomized Clinical Evaluation)<sup>[<xref rid="r10" ref-type="bibr">10</xref>]</sup>p&#x0003e;, RAFT (Resynchronization/Defibrillation for
Ambulatory Heart Failure Trial)<sup>[<xref rid="r11" ref-type="bibr">11</xref>]</sup>p&#x0003e; and MADIT (Multicenter Automatic Defibrillator
Implantation Trial)<sup>[<xref rid="r12" ref-type="bibr">12</xref>]</sup>p&#x0003e; - were carried out in order to elucidate the
indications and guidelines for cardiac resynchronization therapy (CRT) in patients
with chronic HF<sup>[<xref rid="r13" ref-type="bibr">13</xref>-<xref rid="r15" ref-type="bibr">15</xref>]</sup>p&#x0003e;. However, these
studies are not specific for CCC, as this etiology is not common in the countries in
which these trials were conducted.</p><p>For the use of CRT, it is necessary to identify the patients who will respond to this
therapy and those who will not. Studies show that responders and nonresponders can
be identified by clinical (New York Heart Association [NYHA]
functional class, 6-minute walk test, peak oxygen consumption, and quality of life
score) and echocardiographic (improvement in left ventricular ejection fraction
[LVEF], reduction in end-diastolic and end-systolic volume, and
decreasing mitral insufficiency) parameters, as the measurements of these parameters
have already been used to identify responders. However, there is no consensus in the
literature about the relevant responses to this therapy<sup>[<xref rid="r16" ref-type="bibr">16</xref>-<xref rid="r22" ref-type="bibr">22</xref>]</sup>p&#x0003e;.</p><p>Thus, this study aimed to analyze the long-term responses of patients with CCC using
CRT and to estimate the survival rate of responder patients.</p></sec><sec sec-type="methods"><title>METHODS</title><p>This is an observational, cross-sectional and retrospective study. The medical
records of patients with CCC who had cardiac resynchronization devices (multisite
pacemakers) implanted, from June 2009 to March 2017, and who were admitted to Santa
Helena's Hospital were analyzed.</p><p>This study was conducted according to the standards of the National Health Council
(NHC) on research involving humans, as stated in the Resolution 446, adopted
December 12<sup>th</sup>, 2012<sup>[<xref rid="r22" ref-type="bibr">22</xref>]</sup>p&#x0003e;. In this manner, the study was approved by the
Ethics Committee of the Pontif&#x000ed;cia Universidade Cat&#x000f3;lica de
Goi&#x000e1;s (CAAE 46047915 2 0000 0037).</p><p>Data were obtained by reviewing the electronic medical records accessed via doctor's
office - 2014 program and recorded in individual files. The study sample is not
probabilistic, so the records were consecutively included.</p><p>The inclusion criteria were as follows: patients of both sexes with records
available; patients diagnosed with CCC and over 18 years old; patients with NYHA
class II, III or IV; and patients who have been using CRT for at least six months.
Patients who did not meet the inclusion criteria were excluded as well as patients
with incomplete medical records.</p><p>The study variables were as follows: age; sex; CRT duration; comorbidities
(hypertension, diabetes mellitus, smoking, other comorbidities, and the use of an
implantable cardioverter defibrillator [ICD]); medications (including
beta-blockers, angiotensin-converting enzyme [ACE] inhibitor,
angiotensinreceptor blockers [ARB], loop diuretics, thiazide
diuretics, spironolactone, amiodarone, and digoxin); mortality; cause of death;
number of hospitalizations; NYHA functional class before and after CRT; LVEF by
Simpson before and after CRT; QRS duration before and after CRT; and arrhythmias and
blocks (left bundle branch block [LBBB], right bundle branch block
[RBBB], and left anterior fascicular block[LAFB]).</p><p>According to Brazilian guidelines<sup>[<xref rid="r6" ref-type="bibr">6</xref>,<xref rid="r14" ref-type="bibr">14</xref>]</sup>p&#x0003e;,
patients with RBBB and RBBB+LAFB must undergo cardiac magnetic resonance or tissue
Doppler echocardiography to establish the interventricular and intraventricular
dyssynchrony before receiving the CRT system implant.</p><p>To classify patients as responders after six months using CRT, the criteria were as
follows: 1) reduction of at least one point in NYHA class and 2) reduction of 15% in
left ventricular end systolic volume (LVESV).</p><sec><title>Statistical Analysis</title><p>The data were collected and entered into a database using SPSS software, version
18 (SPSS Inc. Released 2009. PASW Statistics for Windows, Version 18.0. Chicago:
SPSS Inc). Descriptive statistics were used to characterize the study
sample.</p><p>Continuous variables were expressed as the mean &#x000b1; standard deviation.
Qualitative variables were evaluated using Chi-square test. Pearson's
correlation was also used to measure the degree of linear relationship between
two quantitative variables.</p><p>Appropriate tests were used to compare the variables as means (Student's t-test).
Survival curves were generated using the Kaplan-Meier method. The results were
presented as the hazard ratio (HR) with 95% confidence interval (95% CI). A
<italic>P</italic> value of &#x0003c;0.05 was considered significant in all
tests.</p></sec></sec><sec sec-type="results"><title>RESULTS</title><p>We analyzed the medical records of 50 patients with CCC undergoing CRT, with an
average CRT duration of 61.2&#x000b1;21.7 months. Of the 50 patients evaluated, 56%
were male and 44% were female. The mean age of the patients was 63.4&#x000b1;13.3
years (<xref ref-type="table" rid="t1">Table 1</xref>).</p><table-wrap id="t1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Patients' characteristics.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/></colgroup><thead><tr><th align="left" colspan="2" rowspan="1">Characteristics</th><th align="center" rowspan="1" colspan="1">No. (%)</th><th align="center" rowspan="1" colspan="1">Mean</th><th align="center" rowspan="1" colspan="1">Standard Deviation</th></tr></thead><tbody><tr><td align="left" rowspan="2" colspan="1">Sex</td><td align="left" rowspan="1" colspan="1">Female</td><td align="center" rowspan="1" colspan="1">22 (44)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">Male</td><td align="center" rowspan="1" colspan="1">28 (56)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" colspan="2" rowspan="1">Age (years)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">63.4</td><td align="center" rowspan="1" colspan="1">13.3</td></tr><tr><td align="left" rowspan="13" colspan="1">Personal history</td><td align="left" rowspan="1" colspan="1">Hypertension</td><td align="center" rowspan="1" colspan="1">21 (42)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">Diabetes mellitus</td><td align="center" rowspan="1" colspan="1">9 (18)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">Current cigarette smoking</td><td align="center" rowspan="1" colspan="1">10 (20)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">Chronic kidney disease</td><td align="center" rowspan="1" colspan="1">6 (12)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">Coronary artery disease</td><td align="center" rowspan="1" colspan="1">5 (10)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">Hypothyroidism</td><td align="center" rowspan="1" colspan="1">4 (8)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">Previous stroke</td><td align="center" rowspan="1" colspan="1">2 (4)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">Hypercholesterolemia</td><td align="center" rowspan="1" colspan="1">1 (2)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">Megacolon</td><td align="center" rowspan="1" colspan="1">1 (2)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">Megaesophagus</td><td align="center" rowspan="1" colspan="1">1 (2)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">Chronic obstructive pulmonary disease</td><td align="center" rowspan="1" colspan="1">1 (2)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">Polyneuropathy</td><td align="center" rowspan="1" colspan="1">1 (2)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">Epilepsy</td><td align="center" rowspan="1" colspan="1">1 (2)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="8" colspan="1">Medication</td><td align="left" rowspan="1" colspan="1">Beta-blockers</td><td align="center" rowspan="1" colspan="1">32 (64)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">ACE inhibitor</td><td align="center" rowspan="1" colspan="1">18 (36)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">ARB</td><td align="center" rowspan="1" colspan="1">24 (48)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">Spironolactone</td><td align="center" rowspan="1" colspan="1">22 (44)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">Loop diuretics/thiazide</td><td align="center" rowspan="1" colspan="1">34 (68)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">Amiodarone</td><td align="center" rowspan="1" colspan="1">35 (70)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">Digoxin</td><td align="center" rowspan="1" colspan="1">15 (30)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">Others</td><td align="center" rowspan="1" colspan="1">29 (58)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="2" colspan="1">Mortality</td><td align="left" rowspan="1" colspan="1">Cardiovascular cause</td><td align="center" rowspan="1" colspan="1">7 (14)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">Other causes</td><td align="center" rowspan="1" colspan="1">6 (12)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">CRT use duration (months)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">61.2</td><td align="center" rowspan="1" colspan="1">21.7</td></tr><tr><td align="left" rowspan="1" colspan="1">ICD use</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">37 (74)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr></tbody></table><table-wrap-foot><fn id="TFN1"><p>ACE=angiotensin-converting enzyme; ARB=angiotensin-receptor blockers;
CRT=cardiac resynchronization therapy; ICD=implantable cardioverter
defibrillator</p></fn></table-wrap-foot></table-wrap><p>Regarding comorbidities, 42% of the patients presented with hypertension, 18% had
diabetes mellitus, 20% were current cigarette smokers and 46% had other
comorbidities (<xref ref-type="table" rid="t1">Table 1</xref>).</p><p>Regarding medications, 64% of patients used beta-blockers, 36% used ACE inhibitors,
48% used ARB, 68% used loop diuretics or thiazide diuretics, 44% used
spironolactone, 70% used amiodarone, 30% used digoxin, and 58% used some other drug
(<xref ref-type="table" rid="t1">Table 1</xref>).</p><p>The use of ICD was reported in 74% of patients (<xref ref-type="table" rid="t1">Table
1</xref>). These patients had indications for the use of ICD before CRT, such as
the presence of complex ventricular arrhythmias, results of electrophysiological
study and secondary prevention.</p><p>The electrophysiological disturbances, like the presence of arrhythmias and bundle
branch blocks, are shown in <xref ref-type="table" rid="t2">Table 2</xref>.
Arrhythmias were identified in patients; nonsustained ventricular tachycardia (VT)
was the most frequently observed arrhythmia (22% of patients), followed by
paroxystic atrial fibrillation/ paroxysmal supraventricular tachycardia (PSVT) (14%)
and sustained VT (6%).</p><table-wrap id="t2" orientation="portrait" position="float"><label>Table 2</label><caption><p>Electrophysiological disturbances of the patients.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/></colgroup><thead><tr><th align="left" colspan="2" rowspan="1">Type</th><th align="center" rowspan="1" colspan="1">Frequency No. (%)</th><th align="center" rowspan="1" colspan="1">Frequency of responders No. (%)</th><th align="center" rowspan="1" colspan="1">Frequency of nonresponders No. (%)</th></tr></thead><tbody><tr><td align="left" rowspan="6" colspan="1">Arrhythmia</td><td align="left" rowspan="1" colspan="1">Ventricular arrhythmia</td><td align="center" rowspan="1" colspan="1">2 (4)</td><td align="center" rowspan="1" colspan="1">2 (4)</td><td align="center" rowspan="1" colspan="1">__</td></tr><tr><td align="left" rowspan="1" colspan="1">Paroxistic atrial fibrillation/PSVT</td><td align="center" rowspan="1" colspan="1">7 (14)</td><td align="center" rowspan="1" colspan="1">5 (10)</td><td align="center" rowspan="1" colspan="1">2 (4)</td></tr><tr><td align="left" rowspan="1" colspan="1">Atrial flutter</td><td align="center" rowspan="1" colspan="1">1 (2)</td><td align="center" rowspan="1" colspan="1">__</td><td align="center" rowspan="1" colspan="1">1 (2)</td></tr><tr><td align="left" rowspan="1" colspan="1">Sustained VT</td><td align="center" rowspan="1" colspan="1">3 (6)</td><td align="center" rowspan="1" colspan="1">3 (6)</td><td align="center" rowspan="1" colspan="1">__</td></tr><tr><td align="left" rowspan="1" colspan="1">Nonsustained VT</td><td align="center" rowspan="1" colspan="1">11 (22)</td><td align="center" rowspan="1" colspan="1">7 (14)</td><td align="center" rowspan="1" colspan="1">4 (8)</td></tr><tr><td align="left" rowspan="1" colspan="1">Not reported</td><td align="center" rowspan="1" colspan="1">26 (52)</td><td align="center" rowspan="1" colspan="1">22 (44)</td><td align="center" rowspan="1" colspan="1">4 (8)</td></tr><tr><td align="left" rowspan="4" colspan="1">Blocks</td><td align="left" rowspan="1" colspan="1">RBBB</td><td align="center" rowspan="1" colspan="1">5 (10)</td><td align="center" rowspan="1" colspan="1">3 (60)</td><td align="center" rowspan="1" colspan="1">2 (40)</td></tr><tr><td align="left" rowspan="1" colspan="1">LBBB</td><td align="center" rowspan="1" colspan="1">15 (30)</td><td align="center" rowspan="1" colspan="1">12 (80)</td><td align="center" rowspan="1" colspan="1">3 (20)</td></tr><tr><td align="left" rowspan="1" colspan="1">LBBB (dual chamber pacing)</td><td align="center" rowspan="1" colspan="1">15 (30)</td><td align="center" rowspan="1" colspan="1">10 (66.6)</td><td align="center" rowspan="1" colspan="1">5 (33.3)</td></tr><tr><td align="left" rowspan="1" colspan="1">RBBB + LAFB</td><td align="center" rowspan="1" colspan="1">15 (30)</td><td align="center" rowspan="1" colspan="1">8 (53.3)</td><td align="center" rowspan="1" colspan="1">7 (46.6)</td></tr></tbody></table><table-wrap-foot><fn id="TFN2"><p>LAFB=left anterior fascicular block; LBBB=left bundle branch block;
PSVT=paroxysmal supraventricular tachycardia; RBBB=right bundle branch
block; VT=ventricular tachycardia</p></fn></table-wrap-foot></table-wrap><p>Sixty percent of the patients had LBBB, while 10% had RBBB; 30% of the patients had
RBBB associated with LAFB. The expressive number of LBBB is due to dual chamber
pacing patients which had done an upgrade to biventricular pacing (30%). Only 8 out
of 30 patients with LBBB (33,3%) did not exhibit a CRT response. Additionally, 2 out
of 5 patients with RBBB (40%) did not also exhibit a CRT response and 7 out of the
15 patients with RBBB + LAFB (46,6%) were also considered nonresponders.</p><p>The average QRS durations were 150.12&#x000b1;12.4 ms and 116.04&#x000b1;2.24 ms before
and after CRT, respectively, showing a statistically significant difference
(<italic>P</italic>&#x0003c;0.001). Only 1 (2%) patient presented a narrow QRS
complex (QRS = 139 ms) before and after therapy. A total of 26 (52%) patients who
had presented with a wide QRS complex (QRS &#x0003e;150 ms) before CRT exhibited a change
to a narrow QRS complex (QRS &#x0003c;120 ms) after CRT. However, despite this change, 5
of these patients (10%) were considered nonresponders.</p><p>The mean LVEF before CRT was 29&#x000b1;7% and the mean LVEF after CRT was
39.9&#x000b1;13.1%, indicating a statistically significant increase in LVEF after CRT
(<italic>P</italic>&#x0003c;0.001) (<xref ref-type="table" rid="t3">Table 3</xref>).
Differently, the LVESV before CRT was 265&#x000b1;59 ml and the mean LVESV after CRT
was 152&#x000b1;59 ml (<italic>P</italic>&#x0003c;0.01). The mean LVEF of the patients
stratified by electrogram abnormalities (LBBB, RBBB, and RBBB+LAFB) before and after
CRT are shown in <xref ref-type="fig" rid="f1">Figure 1</xref>.</p><table-wrap id="t3" orientation="portrait" position="float"><label>Table 3</label><caption><p>Left ventricular ejection fraction before and after CRT use.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="25%" span="1"/><col width="25%" span="1"/><col width="25%" span="1"/><col width="25%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">LVEF</th><th align="center" rowspan="1" colspan="1">Mean</th><th align="center" rowspan="1" colspan="1">Standard Deviation</th><th align="center" rowspan="1" colspan="1"><italic>P</italic> Value <xref ref-type="table-fn" rid="TFN4">*</xref></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Before CRT</td><td align="center" rowspan="1" colspan="1">29%</td><td align="center" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">After CRT</td><td align="center" rowspan="1" colspan="1">39.9 %</td><td align="center" rowspan="1" colspan="1">13.1</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr></tbody></table><table-wrap-foot><fn id="TFN3"><p>CRT=cardiac resynchronization therapy; LVEF=left ventricular ejection
fraction</p></fn><fn id="TFN4"><label>*</label><p><italic>P</italic> value estimated by Student's t-test.</p></fn></table-wrap-foot></table-wrap><p>
<fig id="f1" orientation="portrait" position="float"><label>Fig. 1</label><caption><p>Mean left ventricular ejection fraction (LVEF) according to the bundle
branch blocks presented by the patients before and after cardiac
resynchronization therapy (CRT).</p><p>LAFB=left anterior fascicular block; LBBB=left bundle branch block;
RBBB=right bundle branch block</p></caption><graphic xlink:href="rbccv-33-01-0082-g01"/></fig>
</p><p>With the implementation of CRT, there was a significant improvement in the NYHA
functional class. As shown in <xref ref-type="fig" rid="f2">Figure 2</xref>, the
proportion of patients in NYHA classes III and IV decreased after 24 months of CRT
(from 68 to 12% and from 14 to 6%, respectively) (<italic>P</italic>=0.014). Due to
variations in CRT use duration, the data from 24 months onwards does not correspond
to the total number of patients in the study, although there is a significant
improvement in NYHA class variation over this time.</p><p>
<fig id="f2" orientation="portrait" position="float"><label>Fig. 2</label><caption><p>Variation of New York Heart Association (NYHA) functional class presented
by the patients over the cardiac resynchronization therapy (CRT)
duration.</p></caption><graphic xlink:href="rbccv-33-01-0082-g02"/></fig>
</p><p>Based on evaluation of the improvement in functional class and LVESV individually,
66.6% of patients showed improvement in functional class after six months of CRT.
However, 33.3 % did not exhibit any change in functional class and LVESV after six
months of CRT.</p><p>During the use of CRT, 46% of responder patients required hospitalization, with an
average of 1.5 (&#x000b1;2.2) hospitalizations. The following were the main causes of
hospitalization presented by the patients in the study: ventricular arrhythmias,
atrial arrhythmias, HF exacerbation, appropriate and inappropriate ICD therapies,
pneumonia, chronic obstructive pulmonary disease, urinary tract infection, and
decompensation of diabetes mellitus.</p><p>Death occurred in 25 responder patients (45%), 18 due to cardiovascular causes and 7
due to other causes (<xref ref-type="table" rid="t1">Table 1</xref>). Among the
cardiovascular causes of death were arrhythmias (6%), stroke (2%), acute coronary
syndrome (2%), and decompensation of congestive HF (acute pulmonary edema) (4%).</p><p>The overall survival rate of responder patients estimated by the Kaplan-Meier method
was 100% at 12 months and approximately 45% at 72 months. In the analysis adjusted
by age (&#x0003c;40 years and &#x02265;40 years), the survival rate was the same in both
groups; therefore, there was no difference in response to the therapy due to age.
However, no individuals under 40 years old had used CRT for 60 months (<xref ref-type="fig" rid="f3">Figure 3</xref>).</p><p>
<fig id="f3" orientation="portrait" position="float"><label>Fig. 3</label><caption><p>Kaplan-Meier estimates of survival for cardiac resynchronization therapy
(CRT) responder patients.</p></caption><graphic xlink:href="rbccv-33-01-0082-g03"/></fig>
</p></sec><sec sec-type="discussion"><title>DISCUSSION</title><p>In our study, 56% of the patients were male, with mean age of 63.4 years, as observed
in the literature. One study presented a higher percentage of males, with mean age
ranging from 57.6 to 67.8 years. In another study, the mean age (53&#x000b1;12.1
years) was significantly lower in patients with Chagas disease than in those with
other etiologies (<italic>P</italic>&#x0003c;0.001)<sup>[<xref rid="r23" ref-type="bibr">23</xref>-<xref rid="r25" ref-type="bibr">25</xref>]</sup>p&#x0003e;.</p><p>In the literature, the main heart conditions associated with CCC are complex
ventricular arrhythmias; co-occurring tachyarrhythmias and bradyarrhythmias; and
biventricular HF<sup>[<xref rid="r23" ref-type="bibr">23</xref>]</sup>p&#x0003e;. There is also a combination of LBBB and LAFB that is
quite typical of CCC<sup>[<xref rid="r3" ref-type="bibr">3</xref>]</sup>p&#x0003e;. In our study, 48% of patients showed some
arrhythmia, with 22% exhibiting nonsustained VT and 6% exhibiting sustained VT.
Regarding blocks, 20% had RBBB, 46% had LBBB, and 32% had RBBB+LAFB.</p><p>Studies estimate that a QRS duration of &#x02265;120 ms occurs in 25-50% of patients
with HF<sup>[<xref rid="r26" ref-type="bibr">26</xref>,<xref rid="r27" ref-type="bibr">27</xref>]</sup>p&#x0003e;. In the present study, 98% of
patients already had a QRS duration of &#x0003e;150 ms before the use of CRT, with an
average QRS duration of 150.12 ms. After the use of CRT, that average dropped to
116.04 ms, a significant difference (<italic>P</italic>&#x0003c;0.001) following large
studies, such as COMPANION and MADIT-CRT, and showing that patients with a long QRS
duration benefit from CRT<sup>[<xref rid="r7" ref-type="bibr">7</xref>,<xref rid="r12" ref-type="bibr">12</xref>]</sup>p&#x0003e;.</p><p>Our study showed that 33.3% of patients did not respond to CRT. A study of 72
patients with CCC showed that 65.3% of them responded to CRT at the end of a
follow-up ranging from 4 to 79 months<sup>[<xref rid="r25" ref-type="bibr">25</xref>]</sup>p&#x0003e;. Another study evaluating the use of CRT in
patients with CCC reported that 95.3% of them (20 patients) were responders and that
only 4.7% of patients (1 patient) did not respond to the therapy<sup>[<xref rid="r28" ref-type="bibr">28</xref>,<xref rid="r29" ref-type="bibr">29</xref>]</sup>p&#x0003e;.</p><p>Several studies consider NYHA functional class as an evaluation parameter of the
response to CRT<sup>[<xref rid="r30" ref-type="bibr">30</xref>]</sup>p&#x0003e;. In our study, variations of NYHA class over time
showed that before CRT, 68% of patients were in NYHA class III, 18% in NYHA class II
and 14% in NYHA class IV. After six months of CRT use, only 22% of patients (11
patients) showed no improvement in functional class. A study of the use of CRT in 21
patients with CCC, with a follow-up of over 18 months, showed that 85.7% of patients
had improvements in functional class<sup>[<xref rid="r31" ref-type="bibr">31</xref>]</sup>p&#x0003e;. In the study by Martinelli Filho et
al.<sup>[<xref rid="r25" ref-type="bibr">25</xref>]</sup>p&#x0003e;, 83.8% of patients showed improvement by at least one
functional class, while 16.2% remained in the same functional class or worsened
it.</p><p>In the study of Ara&#x000fa;jo et al.<sup>[<xref rid="r31" ref-type="bibr">31</xref>]</sup>p&#x0003e;, it was possible to verify clinical benefits
of the use of CRT in patients with CCC and at the end of their follow-up, they
showed statistically significant improvements in functional class and LVEF as well
as reduced left ventricular diameter and end-systolic volume, in agreement with our
results.</p><p>Our study showed a significant increase in the mean LVEF before and after the use of
CRT. In agreement with our finding, other studies also showed a significant increase
in this parameter<sup>[<xref rid="r28" ref-type="bibr">28</xref>,<xref rid="r31" ref-type="bibr">31</xref>]</sup>p&#x0003e;.</p><p>A systematic review of predictors of mortality in CCC revealed that symptoms of HF
(NYHA class III/IV), left ventricular impairment on echocardiography, cardiomegaly
on chest radiography and nonsustained VT events in Holter are factors associated
with the risk of death or a worse prognosis; therefore, these symptoms require
stricter interventions<sup>[<xref rid="r23" ref-type="bibr">23</xref>]</sup>p&#x0003e;.</p><p>In our study, the survival rate after 72 months of CRT was 45%, which was lower than
the rate of 50% estimated in the literature after 60 months from the diagnosis of
HF<sup>[<xref rid="r14" ref-type="bibr">14</xref>,<xref rid="r32" ref-type="bibr">32</xref>,<xref rid="r33" ref-type="bibr">33</xref>]</sup>p&#x0003e;.</p><p>Several studies have shown that up to two-thirds of patients with HF are hospitalized
on average twice a year, and the rate of rehospitalization within 3 months reaches
20-30%<sup>[<xref rid="r34" ref-type="bibr">34</xref>]</sup>p&#x0003e;. In our study, the number of hospitalizations was not
related to the CRT use duration (<italic>P</italic>=0.548), but it was significantly
inversely associated with cardiovascular cause of death
(<italic>P</italic>&#x0003c;0.001).</p><p>Another study of the use of CRT with or without ICD showed significant benefits of
the isolated use of CRT and ICD in HF. However, the effect of the combination of
these therapies is not well established as the study data are still
insufficient<sup>[<xref rid="r35" ref-type="bibr">35</xref>]</sup>p&#x0003e;.</p><p>Rassi et al.<sup>[<xref rid="r23" ref-type="bibr">23</xref>]</sup>p&#x0003e;
state that one of the main causes of death in Chagas disease is HF. In a study of
CCC patients using CRT with long-term follow-up, the overall mortality was 34.7% (25
patients). Of these deaths, 76% were due to cardiovascular causes, 8.3% due to
non-cardiovascular causes and 16% due to unknown causes. The worsening of HF was the
main cause of death among the cardiovascular causes (60% of the cases), in agreement
with our results<sup>[<xref rid="r31" ref-type="bibr">31</xref>]</sup>p&#x0003e;.</p><p>Martinelli Filho et al.<sup>[<xref rid="r25" ref-type="bibr">25</xref>]</sup>p&#x0003e;showed that, at the end of the proposed follow-up,
97 (28.2%) deaths were recorded, corresponding to an annual mortality of 6.7%. The
cardiac cause was the main cause of death, corresponding to 84.5% of the known
causes. The authors noted that this increased mortality may have been related to the
high number of patients with advanced atrioventricular block, and they state that
although CRT has a positive impact on the clinical behavior of patients with CCC,
the long-term prognosis is worse compared to other heart diseases<sup>[<xref rid="r25" ref-type="bibr">25</xref>]</sup>p&#x0003e;.</p><sec><title>Limitations</title><p>Our study has some limitations. First, it was a single-center study that included
a limited number of patients. Furthermore, being a retrospective study, the data
were derived from medical records, however, all patients in accordance with
inclusion criteria were studied.</p></sec></sec><sec sec-type="conclusions"><title>CONCLUSION</title><p>This study revealed that a relevant number of patients with CCC using CRT has been
considered as CRT responders (reduction of the NYHA functional class and reduction
of LVESV), otherwise, these patients had no significant improvements in survival
rates after 72 months.</p><table-wrap id="t5" orientation="portrait" position="anchor"><table frame="hsides" rules="groups"><colgroup span="1"><col width="5%" span="1"/><col width="95%" span="1"/></colgroup><thead><tr><th align="left" colspan="2" rowspan="1">Authors' roles &#x00026; responsibilities</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">ASMJ</td><td align="left" valign="top" rowspan="1" colspan="1">Designed the study and performed the
experiments and wrote the manuscript; final approval of the version
to be published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CCL</td><td align="left" valign="top" rowspan="1" colspan="1">Designed the study and performed the
experiments and wrote the manuscript; final approval of the version
to be published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">PFC</td><td align="left" valign="top" rowspan="1" colspan="1">Performed the experiments; final approval
of the version to be published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">EM</td><td align="left" valign="top" rowspan="1" colspan="1">Analyzed the data; final approval of the
version to be published</td></tr></tbody></table></table-wrap></sec></body><back><fn-group><fn fn-type="other"><p>This study was carried out at Escola de Ci&#x000ea;ncias M&#x000e9;dicas,
Farmac&#x000ea;uticas e Biom&#x000e9;dicas of the Pontif&#x000ed;cia Universidade
Cat&#x000f3;lica de Goi&#x000e1;s (PUC-GO), Goi&#x000e2;nia, GO, Brazil.</p></fn><fn fn-type="COI-statement"><p>No conflict of interest.</p></fn></fn-group><fn-group><fn fn-type="financial-disclosure"><p>No financial support.</p></fn><fn fn-type="COI-statement"><p>No conflict of interest.</p></fn></fn-group><ref-list><title>REFERENCES</title><ref id="r1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ciapponi</surname><given-names>A</given-names></name><name><surname>Alcaraz</surname><given-names>A</given-names></name><name><surname>Calder&#x000f3;n</surname><given-names>M</given-names></name><name><surname>Matta</surname><given-names>MG</given-names></name><name><surname>Chaparro</surname><given-names>M</given-names></name><name><surname>Soto</surname><given-names>N</given-names></name><etal/></person-group><article-title>Burden of heart failure in latin america: a systematic review and
meta-analysis</article-title><source>Rev Esp Cardiol (Engl Ed)</source><year>2016</year><volume>69</volume><issue>11</issue><fpage>1051</fpage><lpage>1060</lpage><pub-id pub-id-type="pmid">27553287</pub-id></element-citation></ref><ref id="r2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bello Corassa</surname><given-names>R</given-names></name><name><surname>Aceijas</surname><given-names>C</given-names></name><name><surname>Alves</surname><given-names>PAB</given-names></name><name><surname>Garelick</surname><given-names>H</given-names></name></person-group><article-title>Evolution of Chagas' disease in Brazil. Epidemiological
perspective and challenges for the future: a critical review</article-title><source>Perspect Public Health</source><year>2017</year><volume>137</volume><issue>5</issue><fpage>289</fpage><lpage>295</lpage><pub-id pub-id-type="pmid">27758973</pub-id></element-citation></ref><ref id="r3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rassi Jr</surname><given-names>A</given-names></name><name><surname>Rassi</surname><given-names>A</given-names></name><name><surname>Marin-Neto</surname><given-names>JA</given-names></name></person-group><article-title>Chagas disease</article-title><source>Lancet</source><year>2010</year><volume>375</volume><issue>9723</issue><fpage>1388</fpage><lpage>1402</lpage><pub-id pub-id-type="pmid">20399979</pub-id></element-citation></ref><ref id="r4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vardas</surname><given-names>PE</given-names></name><name><surname>Auricchio</surname><given-names>A</given-names></name><name><surname>Blanc</surname><given-names>JJ</given-names></name><name><surname>Daubert</surname><given-names>JC</given-names></name><name><surname>Drexler</surname><given-names>H</given-names></name><name><surname>Ector</surname><given-names>H</given-names></name><etal/></person-group><article-title>Guidelines for cardiac pacing and cardiac resynchronization
therapy: The Task Force for Cardiac Pacing and Cardiac Resynchronization
Therapy of the European Society of Cardiology. Developed in collaboration
with the European Heart Rhythm Association</article-title><source>Eur Heart J</source><year>2007</year><volume>28</volume><issue>18</issue><fpage>2256</fpage><lpage>2295</lpage><pub-id pub-id-type="pmid">17726042</pub-id></element-citation></ref><ref id="r5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bestetti</surname><given-names>RB</given-names></name><name><surname>Theodoropoulos</surname><given-names>TA</given-names></name><name><surname>Cardinalli-Neto</surname><given-names>A</given-names></name></person-group><article-title>Treating patients with Chagas' cardiomyopathy with chronic heart
failure in the contemporary era</article-title><source>Am Heart J</source><year>2007</year><volume>154</volume><issue>5</issue><elocation-id>e35</elocation-id><pub-id pub-id-type="pmid">17967576</pub-id></element-citation></ref><ref id="r6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martinelli Filho</surname><given-names>M</given-names></name><name><surname>Zimerman</surname><given-names>LI</given-names></name><name><surname>Lorga</surname><given-names>AM</given-names></name><name><surname>Vasconcelos</surname><given-names>JTM</given-names></name><name><surname>Rassi Jr</surname><given-names>A</given-names></name></person-group><article-title>Guidelines for implantable electronic cardiac devices of the
Brazilian Society of Cardiology</article-title><source>Arq Bras Cardiol</source><year>2007</year><volume>89</volume><issue>6</issue><fpage>e210</fpage><lpage>e238</lpage></element-citation></ref><ref id="r7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bristow</surname><given-names>MR</given-names></name><name><surname>Saxon</surname><given-names>LA</given-names></name><name><surname>Boehmer</surname><given-names>J</given-names></name><name><surname>Krueger</surname><given-names>S</given-names></name><name><surname>Kass</surname><given-names>DA</given-names></name><name><surname>De Marco</surname><given-names>T</given-names></name><etal/></person-group><article-title>Cardiac-resynchronization therapy with or without an implantable
defibrillator in advanced chronic heart failure</article-title><source>N Engl J Med</source><year>2004</year><volume>350</volume><issue>21</issue><fpage>2140</fpage><lpage>2150</lpage><pub-id pub-id-type="pmid">15152059</pub-id></element-citation></ref><ref id="r8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cleland</surname><given-names>JG</given-names></name><name><surname>Daubert</surname><given-names>JC</given-names></name><name><surname>Erdmann</surname><given-names>E</given-names></name><name><surname>Freemantle</surname><given-names>N</given-names></name><name><surname>Gras</surname><given-names>D</given-names></name><name><surname>Kappenberger</surname><given-names>L</given-names></name><etal/></person-group><article-title>Longer-term effects of cardiac resynchronization therapy on
mortality in heart failure [the CArdiac REsynchronization-Heart
Failure (CARE-HF) trial extension phase]</article-title><source>Eur Heart J</source><year>2006</year><volume>27</volume><issue>16</issue><fpage>1928</fpage><lpage>1932</lpage><pub-id pub-id-type="pmid">16782715</pub-id></element-citation></ref><ref id="r9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Daubert</surname><given-names>C</given-names></name><name><surname>Gold</surname><given-names>MR</given-names></name><name><surname>Abraham</surname><given-names>WT</given-names></name><name><surname>Ghio</surname><given-names>S</given-names></name><name><surname>Hassager</surname><given-names>C</given-names></name><name><surname>Goode</surname><given-names>G</given-names></name><etal/></person-group><article-title>Prevention of disease progression by cardiac resynchronization
therapy in patients with asymptomatic or mildly symptomatic left ventricular
dysfunction: insights from the European cohort of the REVERSE
(Resynchronization Reverses Remodeling in Systolic Left Ventricular
Dysfunction) trial</article-title><source>J Am Coll Cardiol</source><year>2009</year><volume>54</volume><issue>20</issue><fpage>1837</fpage><lpage>1846</lpage><pub-id pub-id-type="pmid">19800193</pub-id></element-citation></ref><ref id="r10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Young</surname><given-names>JB</given-names></name><name><surname>Abraham</surname><given-names>WT</given-names></name><name><surname>Smith</surname><given-names>AL</given-names></name><name><surname>Leon</surname><given-names>AR</given-names></name><name><surname>Lieberman</surname><given-names>R</given-names></name><name><surname>Wilkoff</surname><given-names>B</given-names></name><etal/><collab>Multicenter InSync ICD Randomized Clinical Evaluation (MIRACLE ICD)
Trial Investigators</collab></person-group><article-title>Combined cardiac resynchronization and implantable cardioversion
defibrillation in advanced chronic heart failure: the MIRACLE ICD
Trial</article-title><source>JAMA</source><year>2003</year><volume>289</volume><issue>20</issue><fpage>2685</fpage><lpage>2694</lpage><pub-id pub-id-type="pmid">12771115</pub-id></element-citation></ref><ref id="r11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>AS</given-names></name><name><surname>Wells</surname><given-names>GA</given-names></name><name><surname>Talajic</surname><given-names>M</given-names></name><name><surname>Arnold</surname><given-names>MO</given-names></name><name><surname>Sheldon</surname><given-names>R</given-names></name><name><surname>Connolly</surname><given-names>S</given-names></name><etal/></person-group><article-title>Cardiac-resynchronization therapy for mild-to-moderate heart
failure</article-title><source>N Engl J Med</source><year>2010</year><volume>363</volume><issue>25</issue><fpage>2385</fpage><lpage>2395</lpage><pub-id pub-id-type="pmid">21073365</pub-id></element-citation></ref><ref id="r12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moss</surname><given-names>AJ</given-names></name><name><surname>Hall</surname><given-names>WJ</given-names></name><name><surname>Cannom</surname><given-names>DS</given-names></name><name><surname>Klein</surname><given-names>H</given-names></name><name><surname>Brown</surname><given-names>MW</given-names></name><name><surname>Daubert</surname><given-names>JP</given-names></name><etal/><collab>MADIT-CRT Trial Investigators</collab></person-group><article-title>Cardiac-resynchronization therapy for the prevention of
heart-failure events</article-title><source>N Engl J Med</source><year>2009</year><volume>361</volume><issue>14</issue><fpage>1329</fpage><lpage>1338</lpage><pub-id pub-id-type="pmid">19723701</pub-id></element-citation></ref><ref id="r13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silva</surname><given-names>RT</given-names></name><name><surname>Martinelli Filho</surname><given-names>M</given-names></name><name><surname>Lima</surname><given-names>CE</given-names></name><name><surname>Martins</surname><given-names>DG</given-names></name><name><surname>Nishi&#x000f3;ka</surname><given-names>SA</given-names></name><name><surname>Pedrosa</surname><given-names>AA</given-names></name><etal/></person-group><article-title>Functional behavior of patients with conventional pacemakers
undergoing cardiac resynchronization</article-title><source>Arq Bras Cardiol</source><year>2008</year><volume>90</volume><issue>2</issue><fpage>138</fpage><lpage>143</lpage><pub-id pub-id-type="pmid">18392387</pub-id></element-citation></ref><ref id="r14"><label>14</label><element-citation publication-type="webpage"><person-group person-group-type="author"><name><surname>Fuganti</surname><given-names>CJ</given-names></name><name><surname>Melo</surname><given-names>CS</given-names></name><name><surname>Moraes Jr</surname><given-names>AV</given-names></name><name><surname>Pachon-Mateos</surname><given-names>JC</given-names></name><name><surname>Pereira</surname><given-names>WL</given-names></name><name><surname>Galv&#x000e3;o Filho</surname><given-names>SS</given-names></name><etal/><collab>Departamento de Estimula&#x000e7;&#x000e3;o Card&#x000ed;aca Artificial
da Sociedade Brasileira de Cirurgia Cardiovascular</collab></person-group><source>Diretrizes: Cardiodesfibrilador implant&#x000e1;vel;
infec&#x000e7;&#x000e3;o em DCEI; papel dos f&#x000e1;rmacos
antiarr&#x000ed;tmicos; dire&#x000e7;&#x000e3;o veicular em portadores de
DCEI</source><date-in-citation content-type="access-date">2016 Jan 21</date-in-citation><comment>Available from: <ext-link ext-link-type="uri" xlink:href="http://www.deca.org.br/Medica/arquivos/SuplementoRelampa.pdf">http://www.deca.org.br/Medica/arquivos/SuplementoRelampa.pdf</ext-link></comment></element-citation></ref><ref id="r15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tracy</surname><given-names>CM</given-names></name><name><surname>Epstein</surname><given-names>AE</given-names></name><name><surname>Darbar</surname><given-names>D</given-names></name><name><surname>Dimarco</surname><given-names>JP</given-names></name><name><surname>Dunbar</surname><given-names>SB</given-names></name><name><surname>NA 3rd</surname><given-names>Estes</given-names></name><etal/></person-group><article-title>2012 ACCF/AHA/HRS focused update of the 2008 guidelines for
device-based therapy of cardiac rhythm abnormalities: a report of the
American College of Cardiology Foundation/American Heart Association Task
Force on Practice Guidelines</article-title><source>J Am Coll Cardiol</source><year>2012</year><volume>60</volume><issue>14</issue><fpage>1297</fpage><lpage>1313</lpage><pub-id pub-id-type="pmid">22975230</pub-id></element-citation></ref><ref id="r16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dickstein</surname><given-names>K</given-names></name><name><surname>Vardas</surname><given-names>PE</given-names></name><name><surname>Auricchio</surname><given-names>A</given-names></name><name><surname>Daubert</surname><given-names>JC</given-names></name><name><surname>Linde</surname><given-names>C</given-names></name><name><surname>McMurray</surname><given-names>J</given-names></name><etal/></person-group><article-title>2010 Focused Update of ESC Guidelines on device therapy in heart
failure: an update of the 2008 ESC Guidelines for the diagnosis and
treatment of acute and chronic heart failure and the 2007 ESC guidelines for
cardiac and resynchronization therapy. Developed with the special
contribution of the Heart Failure Association and the European Heart Rhythm
Association</article-title><source>Eur Heart J</source><year>2010</year><volume>31</volume><issue>21</issue><fpage>2677</fpage><lpage>2687</lpage><pub-id pub-id-type="pmid">20801924</pub-id></element-citation></ref><ref id="r17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fornwalt</surname><given-names>BK</given-names></name><name><surname>Sprague</surname><given-names>WW</given-names></name><name><surname>BeDell</surname><given-names>P</given-names></name><name><surname>Suever</surname><given-names>JD</given-names></name><name><surname>Gerritse</surname><given-names>B</given-names></name><name><surname>Merlino</surname><given-names>JD</given-names></name><etal/></person-group><article-title>Agreement is poor among current criteria used to define response
to cardiac resynchronization therapy</article-title><source>Circulation</source><year>2010</year><volume>121</volume><issue>18</issue><fpage>1985</fpage><lpage>1991</lpage><pub-id pub-id-type="pmid">20421518</pub-id></element-citation></ref><ref id="r18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chung</surname><given-names>ES</given-names></name><name><surname>Leon</surname><given-names>AR</given-names></name><name><surname>Tavazzi</surname><given-names>L</given-names></name><name><surname>Sun</surname><given-names>JP</given-names></name><name><surname>Nihoyannopoulos</surname><given-names>P</given-names></name><name><surname>Merlino</surname><given-names>J</given-names></name><etal/></person-group><article-title>Results of the Predictors of Response to CRT (PROSPECT) trial.
Results of the Predictors of Response to CRT (PROSPECT)
trial</article-title><source>Circulation</source><year>2008</year><volume>117</volume><issue>20</issue><fpage>2608</fpage><lpage>2616</lpage><pub-id pub-id-type="pmid">18458170</pub-id></element-citation></ref><ref id="r19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>J 3rd</surname><given-names>Gorcsan</given-names></name><name><surname>Oyenuga</surname><given-names>O</given-names></name><name><surname>Habib</surname><given-names>PJ</given-names></name><name><surname>Tanaka</surname><given-names>H</given-names></name><name><surname>Adelstein</surname><given-names>EC</given-names></name><name><surname>Hara</surname><given-names>H</given-names></name><etal/></person-group><article-title>Relationship of echocardiographic dyssynchrony to long-term
survival after cardiac resynchronization therapy</article-title><source>Circulation</source><year>2010</year><volume>122</volume><issue>19</issue><fpage>1910</fpage><lpage>1918</lpage><pub-id pub-id-type="pmid">20975000</pub-id></element-citation></ref><ref id="r20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bax</surname><given-names>JJ</given-names></name><name><surname>J 3rd</surname><given-names>Gorcsan</given-names></name></person-group><article-title>Echocardiography and noninvasive imaging in cardiac
resynchronization therapy: results of the PROSPECT (Predictors of Response
to Cardiac Resynchronization Therapy) study in perspective</article-title><source>J Am Coll Cardiol</source><year>2009</year><volume>53</volume><issue>21</issue><fpage>1933</fpage><lpage>1943</lpage><pub-id pub-id-type="pmid">19460606</pub-id></element-citation></ref><ref id="r21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>White</surname><given-names>JA</given-names></name><name><surname>Yee</surname><given-names>R</given-names></name><name><surname>Yuan</surname><given-names>XP</given-names></name><name><surname>Krahn</surname><given-names>A</given-names></name><name><surname>Skanes</surname><given-names>A</given-names></name><name><surname>Parker</surname><given-names>M</given-names></name><etal/></person-group><article-title>Delayed enhancement magnetic resonance imaging predicts response
to cardiac resynchronization therapy in patients with intraventricular
dyssynchrony</article-title><source>J Am Coll Cardiol</source><year>2006</year><volume>48</volume><issue>10</issue><fpage>1953</fpage><lpage>1960</lpage><pub-id pub-id-type="pmid">17112984</pub-id></element-citation></ref><ref id="r22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>K&#x000f8;ber</surname><given-names>L</given-names></name><name><surname>Thune</surname><given-names>JJ</given-names></name><name><surname>Nielsen</surname><given-names>JC</given-names></name><name><surname>Haarbo</surname><given-names>J</given-names></name><name><surname>Videb&#x000e6;k</surname><given-names>L</given-names></name><name><surname>Korup</surname><given-names>E</given-names></name><etal/><collab>DANISH Investigators</collab></person-group><article-title>Defibrillator implantation in patients with nonischemic systolic
heart failure</article-title><source>N Engl J Med</source><year>2016</year><volume>375</volume><issue>13</issue><fpage>1221</fpage><lpage>1230</lpage><pub-id pub-id-type="pmid">27571011</pub-id></element-citation></ref><ref id="r23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rassi Jr</surname><given-names>A</given-names></name><name><surname>Rassi</surname><given-names>A</given-names></name><name><surname>Rassi</surname><given-names>SG</given-names></name></person-group><article-title>Predictors of mortality in chronic Chagas disease: a systematic
review of observational studies</article-title><source>Circulation</source><year>2007</year><volume>115</volume><issue>9</issue><fpage>1101</fpage><lpage>1108</lpage><pub-id pub-id-type="pmid">17339568</pub-id></element-citation></ref><ref id="r24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ruschitzka</surname><given-names>F</given-names></name><name><surname>Abraham</surname><given-names>WT</given-names></name><name><surname>Singh</surname><given-names>JP</given-names></name><name><surname>Bax</surname><given-names>JJ</given-names></name><name><surname>Borer</surname><given-names>JS</given-names></name><name><surname>Brugada</surname><given-names>J</given-names></name><etal/></person-group><article-title>Cardiac-resynchronization therapy in heart failure with a narrow
QRS complex</article-title><source>N Engl J Med</source><year>2013</year><volume>369</volume><issue>15</issue><fpage>1395</fpage><lpage>1405</lpage><pub-id pub-id-type="pmid">23998714</pub-id></element-citation></ref><ref id="r25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martinelli Filho</surname><given-names>M</given-names></name><name><surname>Peixoto</surname><given-names>GL</given-names></name><name><surname>Siqueira</surname><given-names>SF</given-names></name><name><surname>Martins</surname><given-names>SAM</given-names></name><name><surname>Nishioka</surname><given-names>SAD</given-names></name><name><surname>Costa</surname><given-names>R</given-names></name><etal/></person-group><article-title>Terapia de ressincroniza&#x000e7;&#x000e3;o card&#x000ed;aca na
cardiomiopatia chag&#x000e1;sica cr&#x000f4;nica: boa resposta cl&#x000ed;nica
e pior progn&#x000f3;stico</article-title><source>Relampa</source><year>2013</year><volume>26</volume><issue>1</issue><fpage>33</fpage><lpage>38</lpage></element-citation></ref><ref id="r26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silva Menezes</surname><given-names>A</given-names></name></person-group><article-title>Outcome of right ventricular bifocal pacing in patients with
permanent atrial fibrillation and severe dilated cardiomiopathy due to
Chagas disease: three years of follow-up</article-title><source>J Interv Card Electrophysiol</source><year>2004</year><volume>11</volume><issue>3</issue><fpage>193</fpage><lpage>198</lpage><pub-id pub-id-type="pmid">15548885</pub-id></element-citation></ref><ref id="r27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wikstrom</surname><given-names>G</given-names></name><name><surname>Blomstr&#x000f6;m-Lundqvist</surname><given-names>C</given-names></name><name><surname>Andren</surname><given-names>B</given-names></name><name><surname>L&#x000f6;nnerholm</surname><given-names>S</given-names></name><name><surname>Blomstr&#x000f6;m</surname><given-names>P</given-names></name><name><surname>Freemantle</surname><given-names>N</given-names></name><etal/><collab>CARE-HF study investigators</collab></person-group><article-title>The effects of aetiology on outcome in patients treated with
cardiac resynchronization therapy in the CARE-HF trial</article-title><source>Eur Heart J</source><year>2009</year><volume>30</volume><issue>7</issue><fpage>782</fpage><lpage>788</lpage><pub-id pub-id-type="pmid">19168870</pub-id></element-citation></ref><ref id="r28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pereira</surname><given-names>FTM</given-names></name><name><surname>Rocha</surname><given-names>EA</given-names></name><name><surname>Monteiro</surname><given-names>MPM</given-names></name><name><surname>Rocha Neto</surname><given-names>AC</given-names></name><name><surname>Daher</surname><given-names>EF</given-names></name><name><surname>Rodrigues Sobrinho</surname><given-names>CRM</given-names></name><etal/></person-group><article-title>Long-term follow-up of patients with chronic chagas disease and
implantable cardioverter-defibrillator</article-title><source>Pacing Clin Electrophysiol</source><year>2014</year><volume>37</volume><issue>6</issue><fpage>751</fpage><lpage>756</lpage><pub-id pub-id-type="pmid">24467488</pub-id></element-citation></ref><ref id="r29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bestetti</surname><given-names>RB</given-names></name></person-group><article-title>Cardiac resynchronization therapy for patients with chronic
systolic heart failure secondary to Chagas cardiomyopathy in the 21st
century</article-title><source>Rev Bras Cir Cardiovasc.</source><year>2014</year><volume>29</volume><issue>1</issue><fpage>IV</fpage><lpage>VI</lpage></element-citation></ref><ref id="r30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tian</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>P</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Gao</surname><given-names>Y</given-names></name><name><surname>Zhu</surname><given-names>T</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><etal/></person-group><article-title>True complete left bundle branch block morphology strongly
predicts good response to cardiac resynchronization therapy</article-title><source>Europace</source><year>2013</year><volume>15</volume><issue>10</issue><fpage>1499</fpage><lpage>1506</lpage><pub-id pub-id-type="pmid">23468351</pub-id></element-citation></ref><ref id="r31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ara&#x000fa;jo</surname><given-names>EF</given-names></name><name><surname>Chamlian</surname><given-names>EG</given-names></name><name><surname>Peroni</surname><given-names>AP</given-names></name><name><surname>Pereira</surname><given-names>WL</given-names></name><name><surname>Gandra</surname><given-names>SM</given-names></name><name><surname>Rivetti</surname><given-names>LA</given-names></name><etal/></person-group><article-title>Cardiac resynchronization therapy in patients with chronic Chagas
cardiomyopathy: long-term follow up</article-title><source>Rev Bras Cir Cardiovasc</source><year>2014</year><volume>29</volume><issue>1</issue><fpage>31</fpage><lpage>36</lpage><pub-id pub-id-type="pmid">24896160</pub-id></element-citation></ref><ref id="r32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cleland</surname><given-names>JG</given-names></name><name><surname>Abraham</surname><given-names>WT</given-names></name><name><surname>Linde</surname><given-names>C</given-names></name><name><surname>Gold</surname><given-names>MR</given-names></name><name><surname>Young</surname><given-names>JB</given-names></name><name><surname>Claude Daubert</surname><given-names>J</given-names></name><etal/></person-group><article-title>An individual patient meta-analysis of five randomized trials
assessing the effects of cardiac resynchronization therapy on morbidity and
mortality in patients with symptomatic heart failure</article-title><source>Eur Heart J</source><year>2013</year><volume>34</volume><issue>46</issue><fpage>3547</fpage><lpage>3556</lpage><pub-id pub-id-type="pmid">23900696</pub-id></element-citation></ref><ref id="r33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abraham</surname><given-names>WT</given-names></name><name><surname>Fisher</surname><given-names>WG</given-names></name><name><surname>Smith</surname><given-names>AL</given-names></name><name><surname>Delurgio</surname><given-names>DB</given-names></name><name><surname>Leon</surname><given-names>AR</given-names></name><name><surname>Loh</surname><given-names>E</given-names></name><etal/><collab>MIRACLE Study Group</collab></person-group><article-title>Multicenter InSync Randomized Clinical Evaluation. Cardiac
resynchronization in chronic heart failure</article-title><source>N Engl J Med</source><year>2002</year><volume>346</volume><issue>24</issue><fpage>1845</fpage><lpage>1853</lpage><pub-id pub-id-type="pmid">12063368</pub-id></element-citation></ref><ref id="r34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nunes</surname><given-names>MC</given-names></name><name><surname>Dones</surname><given-names>W</given-names></name><name><surname>Morillo</surname><given-names>CA</given-names></name><name><surname>Encina</surname><given-names>JJ</given-names></name><name><surname>Ribeiro</surname><given-names>AL</given-names></name><collab>Council on Chagas Disease of the Interamerican Society of
Cardiology</collab></person-group><article-title>Chagas disease: an overview of clinical and epidemiological
aspects</article-title><source>J Am Coll Cardiol</source><year>2013</year><volume>62</volume><issue>9</issue><fpage>767</fpage><lpage>776</lpage><pub-id pub-id-type="pmid">23770163</pub-id></element-citation></ref><ref id="r35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kalil</surname><given-names>C</given-names></name><name><surname>Nery</surname><given-names>PB</given-names></name><name><surname>Bartholomay</surname><given-names>E</given-names></name><name><surname>Albuquerque</surname><given-names>LC</given-names></name></person-group><article-title>Tratamento com cardioversor-desfibrilador implant&#x000e1;vel e
ressincroniza&#x000e7;&#x000e3;o card&#x000ed;aca: isolados ou
associados?</article-title><source>Rev Bras Cir Cardiovasc</source><year>2006</year><volume>21</volume><issue>1</issue><fpage>85</fpage><lpage>91</lpage></element-citation></ref></ref-list></back></article>